Tags

Type your tag names separated by a space and hit enter

Thymopentin in the treatment of severe alopecia areata.
Dermatologica. 1988; 177(3):170-4.D

Abstract

Since alopecia areata might be due to an aberrant T-cell-mediated immunity, the purpose of our study was to compare the results obtained with Thymopentin to those of topical sensitizing therapies, such as squaric acid dibutylester or diphencyprone. Statistical analysis showed no differences between the results obtained with these two therapies. Therefore, Thymopentin can be considered to be a new therapeutic agent which, like the classic topical drugs squaric acid dibutylester or diphencyprone, has immunoreactive properties and might provide some hope to patients with severe alopecia areata.

Authors+Show Affiliations

Tosti A
Department of Dermatology, University of Bologna, Italy.
Manuzzi P
No affiliation info available
Gasponi A
No affiliation info available

MeSH

Adjuvants, ImmunologicAdolescentAdultAlopecia AreataCyclobutanesCyclopropanesFemaleHumansMaleMiddle AgedPeptide FragmentsThymopentinThymopoietinsThymus Hormones

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

3049174

Citation

Tosti, A, et al. "Thymopentin in the Treatment of Severe Alopecia Areata." Dermatologica, vol. 177, no. 3, 1988, pp. 170-4.
Tosti A, Manuzzi P, Gasponi A. Thymopentin in the treatment of severe alopecia areata. Dermatologica. 1988;177(3):170-4.
Tosti, A., Manuzzi, P., & Gasponi, A. (1988). Thymopentin in the treatment of severe alopecia areata. Dermatologica, 177(3), 170-4.
Tosti A, Manuzzi P, Gasponi A. Thymopentin in the Treatment of Severe Alopecia Areata. Dermatologica. 1988;177(3):170-4. PubMed PMID: 3049174.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Thymopentin in the treatment of severe alopecia areata. AU - Tosti,A, AU - Manuzzi,P, AU - Gasponi,A, PY - 1988/1/1/pubmed PY - 1988/1/1/medline PY - 1988/1/1/entrez SP - 170 EP - 4 JF - Dermatologica JO - Dermatologica VL - 177 IS - 3 N2 - Since alopecia areata might be due to an aberrant T-cell-mediated immunity, the purpose of our study was to compare the results obtained with Thymopentin to those of topical sensitizing therapies, such as squaric acid dibutylester or diphencyprone. Statistical analysis showed no differences between the results obtained with these two therapies. Therefore, Thymopentin can be considered to be a new therapeutic agent which, like the classic topical drugs squaric acid dibutylester or diphencyprone, has immunoreactive properties and might provide some hope to patients with severe alopecia areata. SN - 0011-9075 UR - https://www.unboundmedicine.com/medline/citation/3049174/Thymopentin_in_the_treatment_of_severe_alopecia_areata_ DB - PRIME DP - Unbound Medicine ER -